1. Acetate drives ovarian cancer quiescence via ACSS2-mediated acetyl-CoA production.
- Author
-
Sharrow AC, Megill E, Chen AJ, Farooqi A, Tangudu NK, Uboveja A, McGonigal S, Hempel N, Snyder NW, Buckanovich RJ, and Aird KM
- Subjects
- Female, Humans, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Cell Cycle drug effects, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, Ovarian Neoplasms genetics, Acetyl Coenzyme A metabolism, Acetate-CoA Ligase metabolism, Acetate-CoA Ligase genetics, Acetates metabolism, Acetates pharmacology
- Abstract
Quiescence is a reversible cell cycle exit traditionally thought to be associated with a metabolically inactive state. Recent work in muscle cells indicates that metabolic reprogramming is associated with quiescence. Whether metabolic changes occur in cancer to drive quiescence is unclear. Using a multi-omics approach, we found that the metabolic enzyme ACSS2, which converts acetate into acetyl-CoA, is both highly upregulated in quiescent ovarian cancer cells and required for their survival. Indeed, quiescent ovarian cancer cells have increased levels of acetate-derived acetyl-CoA, confirming increased ACSS2 activity in these cells. Furthermore, either inducing ACSS2 expression or supplementing cells with acetate was sufficient to induce a reversible quiescent cell cycle exit. RNA-Seq of acetate treated cells confirmed negative enrichment in multiple cell cycle pathways as well as enrichment of genes in a published G0 gene signature. Finally, analysis of patient data showed that ACSS2 expression is upregulated in tumor cells from ascites, which are thought to be more quiescent, compared to matched primary tumors. Additionally, high ACSS2 expression is associated with platinum resistance and worse outcomes. Together, this study points to a previously unrecognized ACSS2-mediated metabolic reprogramming that drives quiescence in ovarian cancer. As chemotherapies to treat ovarian cancer, such as platinum, have increased efficacy in highly proliferative cells, our data give rise to the intriguing question that metabolically-driven quiescence may affect therapeutic response., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Katherine Aird reports financial support was provided by American Cancer Society. Katherine Aird reports financial support was provided by National Cancer Institute. Ronald Buckanovich reports financial support was provided by National Cancer Institute. Allison Sharrow reports financial support was provided by Magee-Womens Research Institute and Foundation. Nathaniel Snyder reports financial support was provided by National Cancer Institute. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier GmbH.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF